letrozole has been researched along with Dyslipidemias in 2 studies
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to investigate the effect of LDS on dyslipidemia and hepatic inflammation in rats with letrozole (LET)-induced PCOS and to assess the possible involvement of PCSK9 in these effects." | 8.31 | Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome. ( Agbana, RD; Ajadi, IO; Areloegbe, SE; Areola, ED; Atuma, CL; Fafure, AA; Olaniyi, KS; Olatunji, LA; Sabinari, IW; Shah, MZUH, 2023) |
| " The aim of this study was to investigate the effect of LDS on dyslipidemia and hepatic inflammation in rats with letrozole (LET)-induced PCOS and to assess the possible involvement of PCSK9 in these effects." | 4.31 | Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome. ( Agbana, RD; Ajadi, IO; Areloegbe, SE; Areola, ED; Atuma, CL; Fafure, AA; Olaniyi, KS; Olatunji, LA; Sabinari, IW; Shah, MZUH, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Olaniyi, KS | 1 |
| Areloegbe, SE | 1 |
| Areola, ED | 1 |
| Sabinari, IW | 1 |
| Fafure, AA | 1 |
| Agbana, RD | 1 |
| Atuma, CL | 1 |
| Shah, MZUH | 1 |
| Ajadi, IO | 1 |
| Olatunji, LA | 1 |
| Aliev, DA | 1 |
| Azizov, VA | 1 |
| Sadygova, TA | 1 |
| Zeĭnalov, RS | 1 |
| Musaev, IN | 1 |
1 trial available for letrozole and Dyslipidemias
| Article | Year |
|---|---|
[Lipid metabolism disorders at the breast cancer patients receiving hormonotherapy].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cholesterol, LDL; Dyslipide | 2009 |
1 other study available for letrozole and Dyslipidemias
| Article | Year |
|---|---|
Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome.
Topics: Animals; Dyslipidemias; Female; Humans; Inflammation; Letrozole; NLR Family, Pyrin Domain-Containing | 2023 |